Lumacaftor
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Lumacaftor: Leprosy
One-Sentence Summary
Lumacaftor is a CFTR corrector originally used to treat cystic fibrosis (marketed in Canada as ORKAMBI). The TxGNN model predicts it may be effective for leprosy, but no clinical trials and no publications currently support this prediction. It is a computational signal only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Leprosy |
| TxGNN Prediction Score | 0.9944 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 5 of 5) |
| Number of DINs | 5 (marketed: 5) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general knowledge, lumacaftor is a CFTR corrector that improves the folding and trafficking of F508del-CFTR protein, and its use in cystic fibrosis is established.
Leprosy is a chronic infection caused by Mycobacterium leprae, and no plausible CFTR-related pathway is evident. The high TxGNN score (0.9944) is a computational prediction from the TxGNN model (deep learning) only. It may reflect similarities the model learned between related diseases, not biological evidence, and the prediction is not supported by any trial or publication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02451379 | ORKAMBI | Not specified | Not specified |
| 02483831 | ORKAMBI | Not specified | Not specified |
| 02463040 | ORKAMBI | Not specified | Not specified |
| 02483858 | ORKAMBI | Not specified | Not specified |
| 02537087 | ORKAMBI | Not specified | Not specified |
Safety Considerations
- Drug Interactions: The interaction screening returned 100 interacting drugs. The first 20 returned are summarized below.
- Major: Eliglustat, Naldemedine, Naloxegol, Rolapitant
- Moderate: Acetohexamide, Betamethasone, Bupropion, Dexlansoprazole, Esomeprazole, Glimepiride, Lansoprazole, Linagliptin, Nitisinone, Omeprazole, Pantoprazole, Pioglitazone, Prednisone, Rabeprazole, Ranitidine, Repaglinide
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a TxGNN score, with no clinical trials, no publications, and no plausible mechanistic link between CFTR correction and M. leprae infection. Lumacaftor also carries a substantial interaction burden, so there is no basis to advance.
To proceed, the following is needed:
- Mechanism of action data and a testable biological hypothesis linking CFTR correction to leprosy
- Preclinical or in vitro evidence (e.g., activity against M. leprae or relevant host pathways)
- Health Canada package insert warnings and contraindications, to enable safety screening
- A review of the interaction profile in the context of standard leprosy regimens
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.